Singh Nidhi, Avery Mitchell A, McCurdy Christopher R
Department of Medicinal Chemistry, Laboratory for Applied Drug Design and Synthesis, University of Mississippi, University, MS, 38677-1848, USA.
J Comput Aided Mol Des. 2007 Sep;21(9):511-22. doi: 10.1007/s10822-007-9132-0. Epub 2007 Sep 14.
Mycobacterium tuberculosis 1-deoxy-D: -xylulose-5-phosphate reductoisomerase (MtDXR) is a potential target for antitubercular chemotherapy. In the absence of its crystallographic structure, our aim was to develop a structural model of MtDXR. This will allow us to gain early insight into the structure and function of the enzyme and its likely binding to ligands and cofactors and thus, facilitate structure-based inhibitor design. To achieve this goal, initial models of MtDXR were generated using MODELER. The best quality model was refined using a series of minimizations and molecular dynamics simulations. A protein-ligand complex was also developed from the initial homology model of the target protein by including information about the known ligand as spatial restraints and optimizing the mutual interactions between the ligand and the binding site. The final model was evaluated on the basis of its ability to explain several site-directed mutagenesis data. Furthermore, a comparison of the homology model with the X-ray structure published in the final stages of the project shows excellent agreement and validates the approach. The knowledge gained from the current study should prove useful in the design and development of inhibitors as potential novel therapeutic agents against tuberculosis by either de novo drug design or virtual screening of large chemical databases.
结核分枝杆菌1-脱氧-D-木酮糖-5-磷酸还原异构酶(MtDXR)是抗结核化疗的一个潜在靶点。由于缺乏其晶体结构,我们的目标是构建MtDXR的结构模型。这将使我们能够尽早深入了解该酶的结构和功能,以及它与配体和辅因子的可能结合方式,从而促进基于结构的抑制剂设计。为实现这一目标,使用MODELER生成了MtDXR的初始模型。通过一系列最小化和分子动力学模拟对质量最佳的模型进行了优化。还通过将已知配体的信息作为空间约束条件并优化配体与结合位点之间的相互作用,从目标蛋白的初始同源模型构建了蛋白质-配体复合物。最终模型根据其解释多个定点诱变数据的能力进行了评估。此外,将同源模型与项目后期发表的X射线结构进行比较,结果显示两者高度吻合,验证了该方法的有效性。从当前研究中获得的知识在通过从头药物设计或大型化学数据库虚拟筛选来设计和开发作为潜在新型抗结核治疗药物的抑制剂方面应会证明是有用的。